Aeterna Zentaris Inc banner

Aeterna Zentaris Inc
F:ET8

Watchlist Manager
Aeterna Zentaris Inc Logo
Aeterna Zentaris Inc
F:ET8
Watchlist
Price: 1.4 EUR -2.78% Market Closed
Market Cap: €6.8m

Aeterna Zentaris Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Aeterna Zentaris Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Aeterna Zentaris Inc
F:ET8
Inventory
$1.8m
CAGR 3-Years
106%
CAGR 5-Years
34%
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Inventory
$44.8m
CAGR 3-Years
21%
CAGR 5-Years
146%
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
e
enGene Holdings Inc
NASDAQ:ENGN
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aeterna Zentaris Inc
Glance View

Market Cap
6.8m EUR
Industry
Biotechnology

Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.

ET8 Intrinsic Value
10.9 EUR
Undervaluation 87%
Intrinsic Value
Price

See Also

What is Aeterna Zentaris Inc's Inventory?
Inventory
1.8m USD

Based on the financial report for Sep 30, 2025, Aeterna Zentaris Inc's Inventory amounts to 1.8m USD.

What is Aeterna Zentaris Inc's Inventory growth rate?
Inventory CAGR 5Y
34%

Over the last year, the Inventory growth was -47%. The average annual Inventory growth rates for Aeterna Zentaris Inc have been 106% over the past three years , 34% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett